Related Experiment Video
Updated: Apr 25, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
[New era of the treatment of CRPC in Japan]
1Research Center for Advanced Science and Technology (RCAST), the University of Tokyo.
Abstract:
In Y2014, several new agents targeted to castration resistant(recurrent)prostate cancer; CRPC, are approved in Japan. Although such good news comes 2-3 years behind Western, it may improve the outcomes of the CRPC patients in Japan. In this issue, enzalutamide, abiraterone, and cabazitaxel are discussed by each experts from the productive industries. In addition, the experts from urological field and medical oncology field describe the role of each discipline.
Related Concept Videos
Treatment Resistant Cancers
Targeted Cancer Therapies
There are several types of targeted therapies against...
Treatment Resistent Cancers

